What does platelet activation factor do?
Platelet-activating factor (PAF) is a potent phospholipid mediator that was first described by its ability to cause platelet aggregation and dilation of blood vessels. Now it is also known as a potent mediator of inflammation, allergic responses, and shock.
What stimulates platelet-activating factor?
PAF is produced by stimulated basophils, monocytes, polymorphonuclear neutrophils, platelets, and endothelial cells primarily through lipid remodeling. A variety of stimuli can initiate the synthesis of PAF. These stimuli could be macrophages going through phagocytosis or endothelium cells uptake of thrombin.
Which cells release platelet-activating factor?
PAF is produced by endothelial cells, macrophages, neutrophils, eosinophils, monocytes, and mast cells, and activates many inflammatory cells. PAF plays an important role in normal physiological homeostasis and in the primary response to inflammation and injury.
Does platelet-activating factor cause vasodilation?
Platelet-activating factor (PAF, 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a potent mediator of inflammation that causes neutrophil activation, increased vascular permeability, vasodilation, and bronchoconstriction in addition to platelet activation.
Is Platelet-Activating Factor A protein?
The platelet-activating factor receptor is a G-protein coupled receptor which binds platelet-activating factor. Chr. Chr. The PAF receptor shows structural characteristics of the rhodopsin (MIM 180380) gene family and binds platelet-activating factor (PAF).
What is platelet activation?
Platelet activation is a key process in both protective hemostasis and pathological thrombosis through the activation of multiple pathways by the binding of several agonists (e.g., thromboxane A2 (TxA2), adenosine diphosphate (ADP), and thrombin) to their receptors (Figure 25.1).
Does platelet-activating factor increase vascular permeability?
Activation of platelet-activating factor (PAF) receptor (PAFR) on endothelial cells and leukocytes induces increase in vascular permeability, hypotension, and production of cytokines.
What kind of lipid is platelet-activating factor?
Platelet-activating factor (PAF) is a phospholipid with potent, diverse physiological actions, particularly as a mediator of inflammation.
When do platelets activate?
Platelet activation begins seconds after adhesion occurs. It is triggered when collagen from the subendothelium binds with its receptors (GPVI receptor and integrin α2β1) on the platelet.
What happens after platelet activation?
Platelets are tiny cells in the blood that play a crucial role in maintaining hemostasis by mediating blood clotting at sites of blood vessel damage. When activated, platelets undergo a drastic shape change, become highly adhesive, and secrete many different proteins and chemicals.
What causes platelet activation and aggregation?
This platelet aggregation often occurs when the endothelium is damaged, causing the platelets to become activated as they adhere to the exposed fibrous matrix [11]. Activating the platelets allows them to induce inflammatory responses and thrombus formation [11].
How activated platelet is different from the resting platelet?
Resting platelets retain their discoid shape and can be life-saving for the most vulnerable patients. However, a significant percentage of these platelets are activated, meaning they have changed to a more amorphous form through natural processes.
Which signaling pathways drive cell proliferation in cancer?
Numerous other signaling pathways can of course drive cell proliferation in cancer. Cytokine and RTK signaling, for example, activate STAT3, which stimulates synthesis of Myc and cyclin D (Harrison 2012). Notch, Wnt/β-catenin, and Hedgehog, all of which have been implicated in cancer, also induce Myc and cyclin D (see below).
How can we connect genetic alterations in cancer cells with cancer signaling?
We can connect the genetic alterations in cancer cells with signaling pathways that control processes associated with tumorigenesis and place these in the context of distortions of wider signaling networks that fuel cancer progression. In each case, the result is dysregulated signaling that is not subject to the normal control mechanisms.
How are tyrosine kinases involved in the pathophysiology of cancer?
Oncogenic mutations, amplification, or gene fusions involving upstream tyrosine kinases lead to constitutive signaling through both the Ras-ERK and PI3K-Akt pathways. RTKs including EGFR, ErbB2, fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR) are mutated or amplified in a variety of cancers.
What is the role of PAF receptors in cell adhesion?
A very exciting recent development in which PAF receptors undoubtedly play a role is in the regulation of the function of various cellular adhesion molecules. Finally, there remain many incompletely characterized physiological and pathophysiological situations in which PAF and its receptor play a crucial signalling role.